Cardiac β3‐adrenoceptors—A role in human pathophysiology?
Open Access
- 22 February 2019
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (14) , 2482-2495
Abstract
As β3‐adrenoceptors were first demonstrated to be expressed in adipose tissue they have received much attention for their metabolic effects in obesity and diabetes. After the existence of this subtype had been suggested to be present in the heart, studies focused on its role in cardiac function. While the presence and functional role of β3‐adrenoceptors in the heart has not uniformly been detected, there is a broad consensus that they become up‐regulated in pathological conditions associated with increased sympathetic activity such as heart failure and diabetes. When detected, the β3‐adrenceptor has been demonstrated to mediate negative inotropic effects in an inhibitory G protein‐dependent manner through the NO–cGMP–PKG signalling pathway. Whether these negative inotropic effects provide protection from the adverse effects induced by overstimulation of β1/β2‐adrenoceptors or in themselves are potentially harmful is controversial, but ongoing clinical studies in patients with congestive heart failure are testing the hypothesis that β3‐adrenceptor agonism has a beneficial effect.Linked Articles: This article is part of a themed section on Adrenoceptors—New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetocKeywords
Funding Information
- Ankara Universitesi (15L0237005, 16L0237006, 17L0237002)
- Deutsche Forschungsgemeinschaft (Mi 294/8‐1, SBAG‐115S564)
- Astellas Pharma Canada
This publication has 124 references indexed in Scilit:
- A phase II dose-ranging study of mirabegron in patients with overactive bladderInternational Urogynecology Journal, 2013
- Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) ratAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Cardioprotective Effect of Beta-3 Adrenergic Receptor AgonismJACC, 2012
- Are there functional β3‐adrenoceptors in the human heart?British Journal of Pharmacology, 2011
- Human Urinary Bladder Strip Relaxation by the β-Adrenoceptor Agonist Isoprenaline: Methodological Considerations and Effects of Gender and AgeFrontiers in Pharmacology, 2011
- Human atrial β1L‐adrenoceptor but not β3‐adrenoceptor activation increases force and Ca2+current at physiological temperatureBritish Journal of Pharmacology, 2010
- The selectivity of β‐adrenoceptor agonists at human β1‐, β2‐ and β3‐adrenoceptorsBritish Journal of Pharmacology, 2010
- Effects of β3-Adrenergic Receptor Activation on Rat Urinary Bladder Hyperactivity Induced by OvariectomyThe Journal of Pharmacology and Experimental Therapeutics, 2009
- β3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ currentJournal of Clinical Investigation, 2008
- Immunohistochemical identification of the β3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeineInternational Journal of Obesity, 2002